Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC

Korábbi kezelés

• Patients who previously received hepatic arterial infusion chemotherapy (HAIC), transarterial chemoembolization (TACE), transarterial embolization (TAE), radiotherapy, systemic therapy for HCC
• Prior esophageal and/or gastric varices bleeding
• Use of immunosuppressive medications within 4 weeks prior to the first dose of study treatment
• Major surgical procedure or unhealed wound, ulcer, or fracture within 4 weeks prior to the first dose of study treatment
• Any life-threatening bleeding event within the previous 3 months, including the need for blood transfusion, surgical or localized treatment, or ongoing drug therapy

Más betegség

• Metastatic disease that involves major airways or blood vessels
• History of organ and cell transplantation
• Evidence of portal hypertension with high risk of bleeding
• Severe organ (heart, lung, kidney) dysfunction
• History of other malignancies
• Co-infection with hepatitis B and C viruses
• Human immunodeficiency virus infection

Laborértékek

• Peripheral blood white blood cell count \<3×10\^9/L and platelet count \<50×10\^9/L

Egyéb

• tumor extent ≥70% liver occupation
• Tumor thrombus involving main portal vein or both the first left and right branches of portal vein
• Vena cava invasion
• Central nervous system metastasis
• Hepatic dysfunction, such as ascites, esophagogastric varices, hepatic encephalopathy
• Prolonged prothrombin time \>4 seconds
• Pregnant or lactating patients

• Unresectable HCC (BCLC stage B/C or CNLC II/III) with diagnosis confirmed by histology/cytology or clinically
• At least one measurable untreated lesion
• Intrahepatic tumors can be treated with 1-2 sessions of SIRT
• Child-Pugh score 5-7
• Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1
• Life expectancy of at least 3 months
• Patients with active hepatitis B are allowed, but they need to receive antiviral treatment to achieve a HBV DNA\<10\^3 IU/mL
• Patients with hepatitis C need to finish the anti-HCV treatment